Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Parent-of-origin effect in multiple sclerosis: observations in half-siblings.
Long-term clinical and magnetic resonance imaging outcomes from patients treated with teriflunomide: Results from a phase 2 extension study.
Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.
Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system.
The cost burden of multiple sclerosis in the United States: a systematic review of the literature.
Progress in multiple sclerosis research in the last year.
Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis.
Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial.
Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells.
Liposarcoma concurrence in a multiple sclerosis patient treated with interferon-beta 1b.
Effects of murine and human bone marrow-derived mesenchymal stem cells on cuprizone induced demyelination.
The delta-subunit of the epithelial sodium channel (ENaC) enhances channel activity and alters proteolytic ENaC activation.
Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis.
Santhera receives first product approval: Health Canada approves Catena® for treatment of Friedreich's ataxia
JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level.
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
The potential role of epigenetic modifications in the heritability of multiple sclerosis.
Vinpocetine inhibits oligodendroglial precursor cell differentiation.
Effects of natalizumab treatment on the CSF proteome of multiple sclerosis patients.
Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
Solitary sclerosis: Progressive neurological deficit from a spatially isolated demyelinating lesion: A further report.
The influence of HLA-DRB1*15 on motor cortical pathology in multiple sclerosis.
Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
Dispositional optimism is unidimensional or bidimensional? The Portuguese revised Life Orientation Test.

Pages